Publications
2024
Lenvatinib plus pembrolizumab for untreated advanced renal cell carcinoma: a systematic review and cost-effectiveness analysis.
Fleeman, N., Houten, R., Nevitt, S., Mahon, J., Beale, S., Boland, A., . . . Waddell, T. (2024). Lenvatinib plus pembrolizumab for untreated advanced renal cell carcinoma: a systematic review and cost-effectiveness analysis.. Health technology assessment (Winchester, England), 28(49), 1-190. doi:10.3310/trrm4238
Digital Versus Paper-Based Consent from the UK NHS Perspective: A Micro-costing Analysis.
Houten, R., Hussain, M. I., Martin, A. P., Ainsworth, N., Lameirinhas, C., Coombs, A. W., . . . St John, E. (2025). Digital Versus Paper-Based Consent from the UK NHS Perspective: A Micro-costing Analysis.. PharmacoEconomics - open, 9(1), 27-39. doi:10.1007/s41669-024-00536-0
2023
Upadacitinib for treating moderately to severely active ulcerative colitis [ID3953]
Greenhalgh, J., Mahon, J., Houten, R., Edwards, K., Donegan, S., Boland, A., . . . Mcentee, J. (2023). Upadacitinib for treating moderately to severely active ulcerative colitis [ID3953]: Upadacitinib for treating moderately to severely active ulcerative colitis[ID3953]. Retrieved from https://www.fundingawards.nihr.ac.uk/award/NIHR135585
Correction: Onasemnogene Abeparvovec for Treating Pre-symptomatic Spinal Muscular Atrophy: An External Assessment Group Perspective of the Partial Review of NICE Highly Specialised Technology Evaluation 15.
Chaplin, M., Bresnahan, R., Fleeman, N., Mahon, J., Houten, R., Beale, S., . . . Munot, P. (2023). Correction: Onasemnogene Abeparvovec for Treating Pre-symptomatic Spinal Muscular Atrophy: An External Assessment Group Perspective of the Partial Review of NICE Highly Specialised Technology Evaluation 15.. PharmacoEconomics - open, 7(6), 1015. doi:10.1007/s41669-023-00462-7
Onasemnogene Abeparvovec for Treating Pre-symptomatic Spinal Muscular Atrophy: An External Assessment Group Perspective of the Partial Review of NICE Highly Specialised Technology Evaluation 15
Chaplin, M., Bresnahan, R., Fleeman, N., Mahon, J., Houten, R., Beale, S., . . . Munot, P. (2023). Onasemnogene Abeparvovec for Treating Pre-symptomatic Spinal Muscular Atrophy: An External Assessment Group Perspective of the Partial Review of NICE Highly Specialised Technology Evaluation 15. PharmacoEconomics - Open. doi:10.1007/s41669-023-00439-6
Informed consent failures: National Health Service Resolution data.
Ainsworth, N., Hussain, M. I., Houten, R., Martin, A. P., Toh, S., Rao, C., & St John, E. R. (2023). Informed consent failures: National Health Service Resolution data.. The British journal of surgery, 110(8), 993-995. doi:10.1093/bjs/znad131
Pegcetacoplan for Treating Paroxysmal Nocturnal Haemoglobinuria: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
Bresnahan, R., Houten, R., Greenhalgh, J., Nevitt, S., Mahon, J., Beale, S., . . . Chaplin, M. (2023). Pegcetacoplan for Treating Paroxysmal Nocturnal Haemoglobinuria: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.. PharmacoEconomics - open. doi:10.1007/s41669-023-00408-z
Trastuzumab Deruxtecan for Treating HER2-Positive Unresectable or Metastatic Breast Cancer After Two or More Anti-HER2 Therapies: An Evidence Review Group Perspective of a NICE Single Technology Appraisal
Houten, R., Fleeman, N., Mahon, J., Chaplin, M., Edwards, K., Beale, S., . . . Palmieri, C. (2023). Trastuzumab Deruxtecan for Treating HER2-Positive Unresectable or Metastatic Breast Cancer After Two or More Anti-HER2 Therapies: An Evidence Review Group Perspective of a NICE Single Technology Appraisal. PHARMACOECONOMICS-OPEN. doi:10.1007/s41669-023-00405-2
AN EXAMINATION OF HEALTHCARE PROVIDER COSTS ASSOCIATED WITH PAPER-BASED CONSENT
Houten, R., Hussain, M. I., Ainsworth, N., Rao, C., Lameirinhas, C., Martin, A., & John E, S. (2023). AN EXAMINATION OF HEALTHCARE PROVIDER COSTS ASSOCIATED WITH PAPER-BASED CONSENT. In VALUE IN HEALTH Vol. 26 (pp. S162). Retrieved from https://www.webofscience.com/
Diagnostic accuracy and clinical impact of MRI-based technologies for patients with non-alcoholic fatty liver disease: systematic review and economic evaluation.
Bresnahan, R., Duarte, R., Mahon, J., Beale, S., Chaplin, M., Bhattacharyya, D., . . . Boland, A. (2023). Diagnostic accuracy and clinical impact of MRI-based technologies for patients with non-alcoholic fatty liver disease: systematic review and economic evaluation.. Health technology assessment (Winchester, England), 27(10), 1-115. doi:10.3310/kgju3398
Does a Screening Trial for Spinal Cord Stimulation in Patients With Chronic Pain of Neuropathic Origin Have Clinical Utility (TRIAL-STIM)? 36-Month Results From a Randomized Controlled Trial
Eldabe, S., Nevitt, S., Griffiths, S., Gulve, A., Thomson, S., Baranidharan, G., . . . Duarte, R. V. V. (2023). Does a Screening Trial for Spinal Cord Stimulation in Patients With Chronic Pain of Neuropathic Origin Have Clinical Utility (TRIAL-STIM)? 36-Month Results From a Randomized Controlled Trial. NEUROSURGERY, 92(1), 75-82. doi:10.1227/neu.0000000000002165
Spinal Cord Stimulation for Neuropathic Pain in England From 2010 to 2020: A Hospital Episode Statistics Analysis
Duarte, R. V., Nevitt, S., Houten, R., Brookes, M., Bell, J., Earle, J., . . . Eldabe, S. (2023). Spinal Cord Stimulation for Neuropathic Pain in England From 2010 to 2020: A Hospital Episode Statistics Analysis. NEUROMODULATION, 26(1), 109-114. doi:10.1016/j.neurom.2022.02.229
2022
Screening trials of spinal cord stimulation for neuropathic pain in England-A budget impact analysis
Duarte, R. V., Houten, R., Nevitt, S., Brookes, M., Bell, J., Earle, J., . . . Eldabe, S. (2022). Screening trials of spinal cord stimulation for neuropathic pain in England-A budget impact analysis. FRONTIERS IN PAIN RESEARCH, 3. doi:10.3389/fpain.2022.974904
2021
Pegcetacoplan for treating paroxysmal nocturnal haemoglobinuria [ID3746]
Bresnahan, R., Houten, R., Mahon, J., Beale, S., Nevitt, S., Greenhalgh, J., . . . Gandhi, S. (2021). Pegcetacoplan for treating paroxysmal nocturnal haemoglobinuria [ID3746]: Pegcetacoplan for treating paroxysmal nocturnal haemoglobinuria [ID3746]. Retrieved from https://www.liverpool.ac.uk/population-health/staff/rebecca-bresnahan/
To Trial or Not to Trial Before Spinal Cord Stimulation for Chronic Neuropathic Pain: The Patients' View From the TRIAL-STIM Randomized Controlled Trial
Chadwick, R., McNaughton, R., Eldabe, S., Baranidharan, G., Bell, J., Brookes, M., . . . Sandhu, H. (2021). To Trial or Not to Trial Before Spinal Cord Stimulation for Chronic Neuropathic Pain: The Patients' View From the TRIAL-STIM Randomized Controlled Trial. NEUROMODULATION, 24(3), 459-470. doi:10.1111/ner.13316
A systematic review of health state utility values for thyroid cancer
Houten, R., Fleeman, N., Kotas, E., Boland, A., Lambe, T., & Duarte, R. (2021). A systematic review of health state utility values for thyroid cancer. QUALITY OF LIFE RESEARCH, 30(3), 675-702. doi:10.1007/s11136-020-02676-2
Encorafenib with Binimetinib for the Treatment of Patients with BRAF V600 Mutation-Positive Unresectable or Metastatic Melanoma: An Evidence Review Group Perspective of a NICE Single Technology Appraisal
Houten, R., Greenhalgh, J., Mahon, J., Nevitt, S., Beale, S., Boland, A., . . . McEntee, J. (2021). Encorafenib with Binimetinib for the Treatment of Patients with BRAF V600 Mutation-Positive Unresectable or Metastatic Melanoma: An Evidence Review Group Perspective of a NICE Single Technology Appraisal. PHARMACOECONOMICS-OPEN, 5(1), 13-22. doi:10.1007/s41669-020-00206-x
2020
Brentuximab Vedotin for Treating Relapsed or Refractory CD30-Positive Cutaneous T-Cell Lymphoma: An Evidence Review Group Perspective of a NICE Single Technology Appraisal
Stainthorpe, A., Fleeman, N., Houten, R., Chaplin, M., Boland, A., Beale, S., . . . Syndikus, I. (2020). Brentuximab Vedotin for Treating Relapsed or Refractory CD30-Positive Cutaneous T-Cell Lymphoma: An Evidence Review Group Perspective of a NICE Single Technology Appraisal. PHARMACOECONOMICS-OPEN, 4(4), 563-574. doi:10.1007/s41669-020-00203-0
Does a screening trial for spinal cord stimulation in patients with chronic pain of neuropathic origin have clinical utility and cost-effectiveness (TRIAL-STIM)? a randomised controlled trial.
Eldabe, S., Duarte, R. V., Gulve, A., Thomson, S., Baranidharan, G., Houten, R., . . . Taylor, R. S. (2020). Does a screening trial for spinal cord stimulation in patients with chronic pain of neuropathic origin have clinical utility and cost-effectiveness (TRIAL-STIM)? a randomised controlled trial.. Pain. doi:10.1097/j.pain.0000000000001977
Ixekizumab for treating axial spondyloarthritis after NSAIDs [ID1532]
Greenhalgh, J., Fleeman, N., Houten, R., Chaplin, M., Beale, S., Boland, A., . . . Goodson, N. (2020). Ixekizumab for treating axial spondyloarthritis after NSAIDs [ID1532]: Ixekizumab for treating axial spondyloarthritis after NSAIDs[ID1532]. Retrieved from https://www.liverpool.ac.uk/population-health/staff/janette-greenhalgh/
Lenvatinib and sorafenib for differentiated thyroid cancer after radioactive iodine: a systematic review and economic evaluation
Fleeman, N., Houten, R., Bagust, A., Richardson, M., Beale, S., Boland, A., . . . Shenoy, A. (2020). Lenvatinib and sorafenib for differentiated thyroid cancer after radioactive iodine: a systematic review and economic evaluation. HEALTH TECHNOLOGY ASSESSMENT, 24(2), 1-+. doi:10.3310/hta24020
2019
A systematic review of lenvatinib and sorafenib for treating progressive, locally advanced or metastatic, differentiated thyroid cancer after treatment with radioactive iodine
Fleeman, N., Houten, R., Chaplin, M., Beale, S., Boland, A., Dundar, Y., . . . Shenoy, A. (2019). A systematic review of lenvatinib and sorafenib for treating progressive, locally advanced or metastatic, differentiated thyroid cancer after treatment with radioactive iodine. BMC CANCER, 19(1). doi:10.1186/s12885-019-6369-7
Snapshot quiz 19/16
Rogers, A. C., Elabbas, A., Sahebally, S., & Winter, D. C. (2019). Snapshot quiz 19/16. BRITISH JOURNAL OF SURGERY, 106(13), 1774. doi:10.1002/bjs.11390
2018
Osimertinib for untreated epidermal growth factor receptor (EGFR) mutation-positive non-small-cell lung cancer
Fleeman, N., Mahon, J., Chaplin, M., Boland, A., Beale, S., De Sousa Rego Vieira Duarte, R., . . . Green, J. (2018). Osimertinib for untreated epidermal growth factor receptor (EGFR) mutation-positive non-small-cell lung cancer: Osimertinib for untreated epidermal growth factor receptor (EGFR) mutation-positive non- small-cell lung cancer (17/141/08). NICE Website. Retrieved from https://www.nice.org.uk/guidance/ta621/documents/committee-papers
Brentuximab vedotin for treating relapsed or refractory CD30-positive cutaneous T-cell lymphoma (17/56/12)
Fleeman, N., Stainthorpe, A., Houten, R., Chaplin, M., Boland, A., Beale, S., . . . Isabel, S. (2018). Brentuximab vedotin for treating relapsed or refractory CD30-positive cutaneous T-cell lymphoma (17/56/12): Brentuximab vedotin for treating relapsed or refractory CD30- positive cutaneous T-cell lymphoma (17/56/12). NICE Website. Retrieved from https://www.nice.org.uk/guidance/ta577/documents/committee-papers
2017
WHAT DO THE SINGLE TECHNOLOGY APPRAISALS OF THE PAST TELL US ABOUT FAST-TRACKING THE MOST COST-EFFECTIVE NEW TECHNOLOGIES IN THE FUTURE?
Boland, A., Houten, R., Carroll, C., Kaltenthauer, E., & Dickson, R. (2017). WHAT DO THE SINGLE TECHNOLOGY APPRAISALS OF THE PAST TELL US ABOUT FAST-TRACKING THE MOST COST-EFFECTIVE NEW TECHNOLOGIES IN THE FUTURE?. In VALUE IN HEALTH Vol. 20 (pp. A410). doi:10.1016/j.jval.2017.08.075
What Is the Evidence from Past National Institute of Health and Care Excellence Single-Technology Appraisals Regarding Company Submissions with Base-Case Incremental Cost-Effectiveness Ratios of Less Than £10,000/QALY?
Carroll, C., Houten, R., Boland, A., Kaltenthaler, E., & Dickson, R. C. (2017). What Is the Evidence from Past National Institute of Health and Care Excellence Single-Technology Appraisals Regarding Company Submissions with Base-Case Incremental Cost-Effectiveness Ratios of Less Than £10,000/QALY?. Value in Health, 21(3), 341-350. doi:10.1016/j.jval.2017.09.006
Sorafenib and lenvatinib for treating advanced or metastatic thyroid cancer
Greenhalgh, J. (n.d.). Sorafenib and lenvatinib for treating advanced or metastatic thyroid cancer (ID1059). NICE Website. Retrieved from https://www.nice.org.uk/guidance/ta535/documents/committee-papers
Spondyloarthritis
National Institute for Health and Care Excellence. (2017). Spondyloarthritis: Spondyloarthritis in over 16s: diagnosis and management (NICE Guideline (NG65)). Manchester, UK. Retrieved from https://www.nice.org.uk/guidance/ng65
2016
Palbociclib for treating metastatic, hormone receptor-positive, HER2-negative breast cancer
Greenhalgh, J. (n.d.). Palbociclib for treating metastatic, hormone receptor-positive, HER2-negative breast cancer (ID915). NICE Website. Retrieved from https://www.nice.org.uk/guidance/ta495/documents/committee-papers-2
Ex vivo expanded autologous human corneal epithelial cells for treating moderate to severe limbal stem cell deficiency due to ocular burns
Greenhalgh, J. (n.d.). Ex vivo expanded autologous human corneal epithelial cells for treating moderate to severe limbal stem cell deficiency due to ocular burns (ID899). NICE Website. Retrieved from https://www.nice.org.uk/guidance/ta467/documents/committee-papers-3
Evaluating the use of plerixafor in stem cell mobilisation - an economic analysis of the PHANTASTIC trial
Martin, A. P., Richards, S., Haycox, A., Houten, R., McLeod, C., Braithwaite, B., . . . Clark, R. E. (2016). Evaluating the use of plerixafor in stem cell mobilisation - an economic analysis of the PHANTASTIC trial. JOURNAL OF CLINICAL APHERESIS, 31(5), 434-442. doi:10.1002/jca.21433
Eribulin for locally advanced or metastatic breast cancer
Greenhalgh, J. (n.d.). Eribulin for locally advanced or metastatic breast cancer (ID964). NICE Website. Retrieved from https://www.nice.org.uk/guidance/gid-ta10030/documents/committee-papers
The care of dying people in nursing homes and intensive care units: a qualitative mixed-methods study
Perkins, E., Gambles, M., Houten, R., Harper, S., Haycox, A., O'Brien, T., . . . Ellershaw, J. E. (2016). The care of dying people in nursing homes and intensive care units: a qualitative mixed-methods study. Health Services and Delivery Research, 4(20), 1-410. doi:10.3310/hsdr04200
2015
Coeliac Disease
National Institute for Health and Care Excellence. (2015). Coeliac Disease: Coeliac Disease: Recognition, assessment and management. NICE Guideline. (NG20). Manchester, UK. Retrieved from https://www.nice.org.uk/guidance/ng20
Recognition, assessment, and management of coeliac disease: summary of updated NICE guidance
Downey, L., Houten, R., Murch, S., & Longson, D. (2015). Recognition, assessment, and management of coeliac disease: summary of updated NICE guidance. BMJ-BRITISH MEDICAL JOURNAL, 351. doi:10.1136/bmj.h4513
2014
Through a Glass Darkly: Economics and Personalised Medicine
Haycox, A., Pirmohamed, M., McLeod, C., Houten, R., & Richards, S. (2014). Through a Glass Darkly: Economics and Personalised Medicine. PharmacoEconomics, 32(11), 1055-1061. doi:10.1007/s40273-014-0190-6
Dyspepsia and gastrooesophageal reflux disease
National Institute for Health and Care Excellence. (2014). Dyspepsia and gastrooesophageal reflux disease: Dyspepsia and gastrooesophageal reflux disease: investigation and management of dyspepsia, symptoms suggestive of gastro-oesophagealreflux disease, or both. NICE Guideline (CG184). Manchester, UK. Retrieved from https://www.nice.org.uk/guidance/cg184
Variations in primary care prescribing: lessons to be learnt for GP commissioners
Houten, R., Wailoo, A., Jonsson, P., & McLeod, C. (2014). Variations in primary care prescribing: lessons to be learnt for GP commissioners. PRIMARY HEALTH CARE RESEARCH AND DEVELOPMENT, 15(1), 111-116. doi:10.1017/S1463423613000261
2013
The impact of continuous haemofiltration with high-volume fluid exchange during cardiopulmonary bypass surgery on the recovery of patients with impaired renal function: a pilot randomised trial
Matata, B., Mediratta, N., Morgan, M., Shirley, S., Scawn, N., Kemp, I., . . . Wilson, K. (2013). The impact of continuous haemofiltration with high-volume fluid exchange during cardiopulmonary bypass surgery on the recovery of patients with impaired renal function: a pilot randomised trial. HEALTH TECHNOLOGY ASSESSMENT, 17(49), 1-+. doi:10.3310/hta17490
2012
A pilot randomised controlled trial in intensive care patients comparing 7 days' treatment with empirical antibiotics with 2 days' treatment for hospital-acquired infection of unknown origin
Scawn, N., Saul, D., Pathak, D., Matata, B., Kemp, I., Stables, R., . . . Houten, R. (2012). A pilot randomised controlled trial in intensive care patients comparing 7 days' treatment with empirical antibiotics with 2 days' treatment for hospital-acquired infection of unknown origin. HEALTH TECHNOLOGY ASSESSMENT, 16(36), 1-+. doi:10.3310/hta16360
Evaluation of the Youth Justice Liaison and Diversion (YJLD) Pilot Scheme
Haines, A., Goldson, B., Haycox, A., Houten, R., Lane, S., McGuire, J., . . . Whittington, R. (2012). Evaluation of the Youth Justice Liaison and Diversion (YJLD) Pilot Scheme. London: Department of Health.